Perspective Therapeutics, Inc. — fact timeline

Perspective Therapeutics, Inc. shareholders approved To adjourn the Annual Meeting, if necessary, to ensure that any necessary supplement or amendment to the Proxy Statement is provided or to solicit additional proxies at the 2022-12-13 meeting.

“Proposal Seven – The Adjournment Proposal . The stockholders approved the proposal to adjourn the Annual Meeting, if necessary, to ensure that any necessary supplement or amendment to the Proxy Statement is provided to the Company’s stockholders in a reasonable amount of time in advance of the Annual Meeting or to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve all of the proposals set forth in the Proxy Statement. The votes on this proposal were: For Against Abstain Broker Non-Votes 55,352,480 10,751,723 1,503,207 25,042,495”

Perspective Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers at the 2022-12-13 meeting.

“Proposal Six – The Say-On-Pay Proposal . The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The votes on this proposal were: For Against Abstain Broker Non-Votes 53,042,425 12,745,783 1,819,202 25,042,495”

Perspective Therapeutics, Inc. shareholders approved To ratify the appointment of Assure CPA, LLC as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023 at the 2022-12-13 meeting.

“Proposal Five – The Auditor Ratification Proposal . The stockholders ratified the appointment of Assure CPA, LLC as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023. The votes on this proposal were: For Against Abstain 86,620,297 3,892,087 2,137,521”

Perspective Therapeutics, Inc. shareholders approved Election of four directors to the Board of Directors for a one-year term expiring at the Fiscal 2024 Annual Meeting of Stockholders at the 2022-12-13 meeting.

“Proposal Four – The Election Proposal . The stockholders elected four directors to the Board of Directors for a one-year term expiring at the Fiscal 2024 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. The votes for this proposal were: For Withheld Broker Non-Votes Lori A. Woods 51,255,481 16,351,929 25,042,495 Philip J. Vitale, M.D. 55,318,509 12,288,901 25,042,495 Michael W. McCormick 54,831,641 12,775,769 25,042,495 Alan Hoffmann 55,620,301 11,987,109 25,042,495”

Perspective Therapeutics, Inc. shareholders approved To approve the Plan Amendment to increase the total number of shares of common stock available for awards under the Plan to 46,000,000 shares at the 2022-12-13 meeting.

“Proposal Three – The Equity Incentive Plan Amendment Proposal . The stockholders approved the Plan Amendment. The votes for this proposal were: For Against Abstain Broker Non-Votes 47,983,158 18,875,449 748,803 25,042,495”

Perspective Therapeutics, Inc. shareholders approved To approve the issuance by the Company of shares of Common Stock in an amount equal to 20% or more of the amount of Common Stock issued and outstanding immediately prior to such issuance at the 2022-12-13 meeting.

“Proposal Two – The NYSE American Proposal . The stockholders approved the issuance by the Company of shares of Common Stock, par value $0.001 per share, in an amount equal to 20% or more of the amount of Common Stock issued and outstanding immediately prior to such issuance. The votes for this proposal were: For Against Abstain Broker Non-Votes 56,946,259 9,128,897 1,532,254 25,042,495”

Perspective Therapeutics, Inc. shareholders voted on To approve an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares of Common Stock at the 2022-12-13 meeting.

“The results of the voting as of the date of the Annual Meeting on December 13, 2022 were as follows: For Against Abstain Broker Non-Votes 52,741,902 14,178,373 687,135 25,042,495”

Perspective Therapeutics, Inc. entered into New 2024 Agreement with Joint Stock Company «Isotope» (effective 2022-12-12).

“Additionally, on December 12, 2022, Medical entered into a supply contract (the “ New 2024 Agreement ”) with JSC Isotope.”

Perspective Therapeutics, Inc. entered into New 2023 Agreement with Joint Stock Company «Isotope» (effective 2022-12-12).

“On December 12, 2022, Isoray Medical, Inc. (“ Medical ”), a wholly owned subsidiary of Isoray, Inc. (the “ Company ”), entered into a supply contract (the “ New 2023 Agreement ”) with Joint Stock Company «Isotope», a Russian company (“ JSC Isotope ”).”

Perspective Therapeutics, Inc. entered into Promissory Note and Security Agreement with Viewpoint Molecular Targeting, Inc. valued at $6,000,000 (effective 2022-11-22).

“On November 22, 2022, Isoray, Inc. (the “ Company ”) entered into a Promissory Note and Security Agreement (the “ Note ”) with Viewpoint Molecular Targeting, Inc., a Delaware corporation (“ Viewpoint ”), pursuant to which the Company loaned the amount of $6,000,000 to Viewpoint (the “ Loan ”). The Note bears interest at the rate of 15% per annum, matures on December 31, 2023, and is secured by a first-priority security interest in all of Viewpoint’s present and after-acquired personal property. The unpaid balance plus all accrued interest and other amounts payable under the Note may be accelerated upon an event of default thereunder. Proceeds of the Loan are to be used by Viewpoint for business expenses in accordance with a budget provided to the Company. The above description is only a summary of the Note, does not purport to be a complete description of the Note, and is qualified in its entirety by reference to the Note, a copy of which is filed as Exhibit 10.1 and incorporated herei”

Perspective Therapeutics, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: revenue $1.72 million, net income $4.07 million or ($0.03) per basic and diluted share.

“Revenue for the first quarter of fiscal 2023 decreased 33% to $1.72 million versus $2.56 million in the prior year comparable period.”